American CryoStem Selected as "Incubator Company of the Year" by New Jersey Business Incubation Network (NJBIN)

EATONTOWN, N.J., April 9, 2014 (GLOBE NEWSWIRE) -- American CryoStem Corporation (OTCQB:CRYO), a leading biotechnology developer and global licensor of patented adipose tissue-based adult stem cell technologies, today announced that the Company has been selected as an "Incubator Company of the Year" by the New Jersey Incubation Network ("NJBIN"). The award will be presented at NJBIN's upcoming Second Annual Business Incubation Awards to be held on April 25, 2014 at the EcoComplex – Rutgers University's Alternative Energy Innovation and Environmental Research & Extension Center in Bordentown Township, New Jersey.

John Arnone, CEO of American CryoStem commented, "We would like to recognize and thank the NJBIN and the Burlington County High Technology and Life Sciences Incubator for selecting our Company for this award. Our ability to locate and develop our technology at the Incubator has afforded us greater opportunities to build our pipeline, create collaborations and widen our commercial horizon."

NOTE TO PRESS: To arrange a one-on-one interview with the Company, please contact Kathy Addison at Hanover|Elite at 407-585-1080 or via email at

About New Jersey Business Incubation Network

The New Jersey Business Incubation Network (NJBIN) is a collaborative statewide community of business experts and resource facilities dedicated to enhancing the commercial success of early stage and expansion stage entrepreneurial companies; growing higher paying jobs, and supporting the economic growth strategy for the state. Early stage and expansion stage companies receive critical support services and flexible space in a professional business environment. For more information, please visit NJBIN at

About American CryoStem Corporation

A biotechnology pioneer in the fields of Regenerative and Personalized Medicine, American CryoStem operates a state-of-the-art, FDA-registered, clinical laboratory dedicated to processing, bio-banking and development of cellular applications using autologous adipose (fat) tissue and adipose derived stem cells (ADSCs). Through its scientific efforts, the Company has built a strong, strategic portfolio of intellectual property, patent applications, and proprietary operating processes that form its core standardized cellular platform. For more information, please visit and You can also find us on Facebook and Twitter.


Contact Data